Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week's Featured Article
The Often-Missed Corner of Healthcare That Wall Street Is LovingBy Nathan Reiff. Publication Date: 3/29/2026. 
Key Points
- Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to see some of the wildest spikes and drops across the market. Investors who want exposure to the healthcare space but are wary of that turbulence may prefer a "picks and shovels" approach: focusing on companies that provide essential equipment and services to the industry rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked, even though some firms in this subindustry are among the largest in healthcare. With a range of external factors potentially affecting healthcare in 2026—shifting subsidies, an aging population, inflation, the growing role of AI, and more—core lab equipment names may be especially appealing. The companies below are major players worth a closer look for investors considering this industry. A Recent Dip Masks Thermo Fisher's Long-Term Strengths
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund.
It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you."
This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story.
$182-billion life sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026. Shares are down more than 15% year-to-date (YTD), and the company recently slipped into TradeSmith's red zone for financial health. Much of that recent weakness appears tied to tariffs and foreign-exchange volatility, which combined to reduce margins by more than 100 basis points in 2025. There are, however, several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue of $12.2 billion rose 7% year-over-year (YOY), beating analyst estimates by roughly $250 million. Adjusted earnings per share (EPS) also topped expectations at $6.57. That momentum may reflect a string of product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Thermo Fisher's broad business mix could provide ample cushion against external pressures. Despite tepid guidance for 2026—revenue is expected to rise 4% to 6%—improving EBITDA margins are a positive, and underlying customer demand looks resilient. This may explain why analysts remain upbeat: 17 of 19 rate the company a Buy or equivalent, and consensus estimates imply more than 29% upside potential. Danaher's Business May Be Improving, Even as Guidance Remains ModestDanaher Corp. (NYSE: DHR) shares are down nearly 20% YTD as the instruments, consumables, and reagents firm navigates a similar environment to Thermo Fisher. 2026 guidance calls for modest core revenue growth of 3% to 6% YOY, but the latest quarter included both a top- and bottom-line beat and $5.3 billion in free cash flow for 2025. Two bright spots are Danaher's bioprocessing business—expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand—and diagnostics. Diagnostics should benefit from recent FDA clearances, and equipment orders have started to improve after a prolonged slump, supporting potential sales growth. Analysts are fairly optimistic about DHR, projecting about 12.3% earnings growth in the year ahead and roughly 35% potential share-price appreciation. No surprise, then, that 19 of 22 analyst ratings on DHR are Buys. Agilent's Biocare Purchase Could Be a CatalystAgilent Technologies (NYSE: A) appears a bit behind the companies above based on its latest earnings, which showed only 4.4% YOY revenue growth and marginal misses on both revenue and earnings versus expectations. However, Agilent's recent acquisition of Biocare Medical could provide a growth engine by strengthening its position in cancer diagnostics. Although the Biocare purchase cost nearly $1 billion, it should add recurring revenue in an area with rising demand. Cancer diagnostics can be higher-margin than some of Agilent's existing lines, which could help expand operating margin (it was 24.6% last quarter). Despite a roughly 17% YTD decline, analysts see about 42% upside for Agilent. Wall Street rates the stock a Moderate Buy overall, with 13 of 16 analysts recommending Buy or a similar rating. |
